Literature DB >> 4040861

Six-month chemotherapy for urogenital tuberculosis.

V Skutil, J Varsa, M Obsitník.   

Abstract

Rifampicin (RMP, 600 mg), isoniazid (INH, 300 mg) and pyrazinamide (PZA, 1,000 mg) administered daily in the hospital for a duration of 2 months was followed at home by daily administration of 600 mg RMP and 300 mg INH for a duration of 4 months. 113 patients with previously untreated and bacteriologically proven urogenital tuberculosis were admitted to the study. Therapy was completed and evaluated in 106 (94%) patients. No failure of chemotherapy was observed during the treatment; one bacteriologically proven relapse occurred after completion of treatment within the 45- to 63-month follow-up. This 6-month chemotherapy seems as efficient as the standard treatment which lasted for 18-24 months.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040861     DOI: 10.1159/000472484

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

1.  [Genitourinary tuberculosis in Germany: diagnosis and treatment].

Authors:  S Lenk
Journal:  Urologe A       Date:  2011-12       Impact factor: 0.639

2.  Urolithiasis associated with urogenital tuberculosis. Clinical and mineralogical aspects.

Authors:  S Lenk; G Schubert; H Oesterwitz; G Brien
Journal:  Urol Res       Date:  1988

3.  Urogenital tuberculosis: update and review of 8961 cases from the world literature.

Authors:  André A Figueiredo; Antônio M Lucon
Journal:  Rev Urol       Date:  2008

4.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.